At the American Academy of Ophthalmology (AAO) annual meeting in San Francisco, Zeiss is presenting the latest in digital eye care innovation and high-resolution imaging.
“Zeiss has set the pace in digital advancements, collaborating with leading doctors and scientists around the world with integrated, data-driven solutions,” Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec, said in a company news release. “We’re excited to be here at AAO, demonstrating our commitment to providing customers with innovative platforms, so they can provide their patients with digital care every step of the way.”
The Zeiss Integrated Diagnostic Imaging platform, a software-driven, multi-modality solution that gathers, combines and associates data from different diagnostics devices, allows doctors to individualize treatment to their patients’ specific needs, creating a digital workflow that enhances treatment capabilities and expands the level of care.
With the onset of new technologies and vast amounts of information that doctors are required to absorb, fast and high-quality diagnostics are critical for creating customized treatment regimens enabling clinicians to spend more time with their patients. With the Integrated Diagnostic Imaging platform, Zeiss creates a digital workflow using solutions like the Cirrus 6000 and the Zeiss Glaucoma Workplace.
The Zeiss Cirrus 6000, the next generation, ultra-fast 100kHz system, aims to elevate the efficiency of busy, advanced care practices. At 100,000 scans-per-second, image acquisition is extremely fast. The Zeiss Cirrus 6000 OCT scans are 270 percent faster than prior Cirrus generations, 43 percent faster than the Zeiss Cirrus 5000, and Zeiss AngioPlex and OCT cube scans can be acquired in as little as 0.4 seconds. Seamless transfer of raw patient data from previous generations makes it easy to analyze and preserve old, new, and future patient data.
The Zeiss Glaucoma Workplace integrates perimetry and OCT to help doctors streamline complex analysis. The new version of the Zeiss Glaucoma Workplace features a new Progression Summary report with “exception-based” alerts that automatically display statistically significant change in critical measurements such as Visual Field, RNFL, GCL, C/D Ratio and IOP change. The Zeiss Glaucoma Workplace helps deliver a new level of efficiency for glaucoma data analysis.
In addition to the Zeiss Integrated Diagnostic Imaging platform, the Zeiss SL 800 offers further innovative and ergonomic workflow improvements for a more straight-forward, uninterrupted eye exam that frees up one of the doctor’s hands. Equipped with AutoView, a motorized two-button mechanism for changing magnification right next to the joystick, an electronic QuickStop brake, and the unique VarioLight feature that combines all advantages of LED and halogen illumination characteristics, Zeiss SL 800 facilitates more focus on doctor-to-patient interaction and sets a new standard in slit lamps.
The Artevo 800, the first digital microscope in ophthalmic surgery, is now commercially available in the United States. The Zeiss Artevo 800 was developed with surgeons for surgeons and includes integrated digital optics for optimized digital visualization and cloud connectivity to the EQ Workplace for remote access to patient data and images.
“I am thrilled with the digital microscope,” Sri Ganesh, MD, Chairman and Managing Director of Nethradhama Super Speciality Eye Hospital, Bangalore, India, said in the news release. “The visualization is amazing – I don’t miss my oculars at all.”
“We are excited to offer surgeons an improved surgical experience with the commercially-available Zeiss Artevo 800,” Jim Mazzo, Global President Ophthalmic Devices at Carl Zeiss Meditec, said in the news release. “With revolutionizing visualization, information, comfort and workflow in the operating room, the Artevo 800 is going to change the future of surgical care.”
The Zeiss Artevo 800 brings the proven strengths of Zeiss optic engineering together with the countless capabilities of digital imaging and embeds that into the workflow of the company’s Cataract Suite with a full range of diagnostic and surgical products. With Zeiss Artevo 800, Zeiss is entering a new era of digital ophthalmic visualization, allowing customers to see more.
Additionally, Zeiss is expanding its data management system FORUM with the Zeiss EQ Workplace, allowing customers to remotely plan IOL surgery to streamline their refractive cataract workflow. Along with Zeiss Veracity Surgical, Zeiss offers digital workflow solutions for a wide variety of customer preferences and infrastructure requirements.
Zeiss demonstrates its commitment to the U.S. refractive market with the MEL 90 clinical trial across eight investigational sites. Zeiss is bringing new refractive technologies to the U.S. market, starting with the VisuMax laser for SMILE and continuing with the MEL 90.
With more than 2 million Small Incision Lenticule Extraction treatments to date, Zeiss continues its leadership in laser vision correction with SMILE currently used by more than 2,000 surgeons across more than 70 countries worldwide. With FDA approval late last year, Zeiss expanded its Myopia treatment to patients with Astigmatism and has seen the volume of treatments with SMILE more than double in the U.S. compared to last year.
“As one of the first surgeons in California to perform the SMILE based procedure I have since seen a drastic improvement in patient care,” Jay Bansal, MD, of the LaserVue Eye Center in the San Francisco Bay Area, said in the news release. “The minimally-invasive nature of the procedure improves the overall patient experience and the solution set up makes it more efficient and economical for my practice.”
SMILE supports a minimally-invasive corneal refractive procedure performed by using the VisuMax femtosecond laser to create a thin disc-shaped lenticule within the cornea, which is then removed through a small incision, thereby achieving the desired vision correction. SMILE requires only one laser to perform the entire solution leaving the outer corneal layer largely intact, thus potentially contributing to the cornea’s biomechanical and refractive stability after surgery.
As some indications in refractive surgery still require treatment by an ablative laser, Zeiss has initiated a clinical trial for the MEL 90 Excimer Laser. With IDE approval received earlier this year, first treatments have commenced prior to AAO. “We are thrilled to be starting this study now and to eventually support an approval that will complement our surgical toolbox beyond the indications of the SMILE based procedure,” said Jon Dishler, MD, of Dishler Laser in Denver, Colorado, and Medical Monitor for the MEL 90 clinical trial.
Zeiss will showcase the latest solutions for digital eye care in Booth # 5669 in North Hall at the Annual Meeting of the American Academy of Ophthalmology (AAO) from October 12-15, 2019.